VRTX

Vertex Pharmaceuticals Inc

528.04

+30.03+6.03%

After Hours: 528.00 -0.04 -0.01%19:57 07/02 EDT

Daily

Weekly

Monthly

Quarterly

Yearly

OPEN/PREV CLOSE503.76/498.01

TODAY RANGE501.53-529.14

VOL1.88M

MARKET CAP134.02B

52 WEEK RANGE362.50-529.14

AVG VOL (3M)1.42M

% TURNOVER0.74%

TURNOVER--

P/E (TTM)31.31

% RANGE5.54%

EPS(TTM)16.87

P/E(FORWARD)30.97

P/B6.93

BVPS76.18

DIVIDEND--

P/S11.18

BETA--

DIV YIELD0.00%

FREE FLOAT MKT CAP133.73B

SHARES OUTSTANDING253.81M

NEXT EARNINGS08/03-08/07

FREE FLOAT253.25M

LOT SIZE1

EX-DATE08/24/2000

News

Press Releases

Financial Reports

Profile

Simply Wall St·6h ago
Is Vertex Pharmaceuticals (VRTX) Undervalued After CASGEVY Won Expanded FDA Approval?
Simply Wall St·1d ago
Vertex (VRTX) Just Won FDA Approval To Treat 5,500 More Young Children
NASDAQ·1d ago
Wall Street Bulls Look Optimistic About Vertex (VRTX): Should You Buy?
Dow Jones·2d ago
Vertex Pharmaceuticals Inc. Stock Advances 6.0%, Outperforms Peers
NASDAQ·2d ago
Weekly Buzz: VRTX, APTX Gain FDA Nod; UNCY Disappoints; Ipsen Opens Wallet; VTGN Misses Goal
Benzinga·2d ago
Vertex Says Casgevy Label Expansion Opens Treatment to 5,500 More Us Children
Benzinga·2d ago
Reported Earlier, Vertex Wins FDA Approval Expanding CASGEVY Use To Children As Young As 2 With Severe Sickle Cell Disease Or Beta Thalassemia
NASDAQ·2d ago
Vertex Expands FDA Approval For CASGEVY In Children With Sickle Cell Disease And Beta Thalassemia
TipRanks·3d ago
Vertex announces FDA approval for expanded use of Casgevy
PUBT·3d ago
Vertex says FDA expands Casgevy approval to sickle cell, beta thalassemia patients age 2+
Reuters·3d ago
VERTEX ANNOUNCES US FDA APPROVAL FOR EXPANDED USE OF CASGEVY® FOR THE TREATMENT OF PEOPLE AGES 2 YEARS AND OLDER WITH SICKLE CELL DISEASE OR TRANSFUSION-DEPENDENT BETA THALASSEMIA
Dow Jones·3d ago
Vertex Pharmaceuticals Gets FDA OK for Sickle Cell Disease Treatment in Young Children
Reuters·3d ago
US FDA approves Vertex's gene therapy for sickle cell disease in children as young as two
Seeking Alpha·3d ago
Vertex gains expanded indication for Casgevy in children as young as two
Benzinga·3d ago
FDA Approves First Gene Therapy for Young Children with Sickle Cell Disease; The FDA Granted The Approval To Vertex Pharmaceuticals

Same Industry

Name/Symbol

Change%

Price

McKesson

MCK

-0.04%

763.51

Biogen Inc

BIIB

+6.97%

216.03

Amgen Inc

AMGN

+1.56%

358.33

Shire

SHPG

0.00%

179.20

CELG-RT

Lilly Eli & Co

LLY

+7.13%

Celgene

CELG

0.00%

108.24

Therapeuticsmd Inc

TXMD

+3.94%

2.110

Johnson & Johnson

JNJ

+0.89%

256.93

Abbvie Inc

ABBV

+4.20%

253.35

Zoetis Inc

ZTS

-2.22%

76.09

Gilead Sciences Inc

GILD

-1.21%

126.33

Novo-Nordisk A/S

NVO

-0.83%

47.94

Bristol-Myers Squibb Co

BMY

+4.16%

58.13

ALXN

Pfizer

PFE

+2.62%

24.29

SNY

Sanofi FR

GCVRZ

0.00%

0.8711

Novartis

NVS

+1.40%

157.59

Dr Reddys Labs

RDY

-3.06%

14.91

No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.